TECH

Bio-Techne

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/06/26

Business Summary

TECH operates within Biotechnology, generating cash by developing and supplying specialized tools, reagents, and solutions that support research and clinical applications across the Healthcare ecosystem. Its model benefits from recurring demand tied to ongoing scientific experimentation and drug development cycles rather than single-product dependency. The moat stems from embedded relationships with research institutions and biopharma clients that rely on validated, high-quality inputs where switching costs can be operationally disruptive. Scale, reputation, and integration into customer workflows create stickiness that underpins institutional ownership of 73.50% and supports sustained capital access.

VALUATION

P/E

105.3

Market Cap ($M USD)

$8,689

Forward P/E

25.7

PEG

5.6

PRICE TO SALES

7.2

PRICE TO BOOK

4.3

EV / EBITDA

39

5-Year Average P/E

DIVIDEND

Yield

0.60%

Annual Payout

$0.32

Payout Ratio

60.40%

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

0.00%

Financial Health & Profitability

Earnings Per Share

$0.53

Next Year EPS Growth Estimate

$2.16

Next Year Revenue Growth Estimate

6.30%

Return on Equity (ROE)

4.00%

Operating Margin

21.20%

Debt-to-Equity

0.2

Piotroski F-Score

7

Altman Z-Score

11.9

Return on Invested Capital (ROIC)

3.80%%

Current Ratio

4.5

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 105.3x earnings with a Forward P/E of 25.7, the market is clearly pricing in a dramatic earnings normalization story, yet the PEG Forward of 5.6 suggests that growth expectations are already stretched relative to projected expansion. A 4.00% operating margin and 6.30% ROE do not justify a triple-digit trailing multiple, even if earnings inflect next year. However, the Altman Z-Score of 11.9 and a Current Ratio of 4.5 signal fortress-level balance sheet stability, meaning insolvency risk is negligible. This is not a distressed mispricing—it’s a quality balance sheet wrapped in an aggressively valued growth narrative that must execute flawlessly to justify its premium.

AI Exposure / Tech Reliance

As a Biotechnology company listed on Nasdaq within Healthcare, TECH operates in a sector increasingly shaped by AI-driven drug discovery and data-intensive research workflows. Biotechnology firms that integrate advanced analytics and automation into R&D processes can enhance efficiency and defensibility. The company’s ability to remain technologically relevant will depend on embedding data-driven tools into its scientific and product infrastructure.

The Bull Case

A GARP investor could justify ownership based on financial durability and improving earnings trajectory implied by the steep compression from a 105.3 P/E to a 25.7 Forward P/E. The Piotroski F-Score of 7 indicates solid operational quality with improving fundamentals rather than deterioration. Debt/Equity of 21.20% combined with an Altman Z-Score of 11.9 and a 4.5 Current Ratio reflects conservative leverage and exceptional liquidity, which reduces downside risk. While ROIC at 3.80% and ROE at 6.30% are not elite, they are positive and supported by institutional sponsorship of 73.50%, suggesting that large capital allocators see durable value in the franchise.

The Bear Case

The bear case is rooted in valuation excess and weak profitability metrics. A PEG Forward of 5.6 screams overvaluation relative to growth, while a 4.00% operating margin and 3.80% ROIC indicate mediocre capital efficiency for a company trading at 7.2x sales and 4.3x book. The 105.3 trailing P/E leaves no room for execution error, and with EPS Next Year estimated at $0.53 against a current EPS of 39, the earnings profile appears volatile or inconsistent. With a negligible TTM Yield of 0.2 and a 0.00% Short % of Float, there is little income support and limited contrarian fuel if sentiment turns.

Market Sentiment & Smart Money

Short Interest %

9.00%

Analyst Consensus

1.67

Average Analyst Price Target

$73.50

Institutional Ownership %

114.00%

1-Year Beta

1.28

Insider Buying % (6 Mo)

0.30%%

Distance to 52-Week High

77.00%%

Distance to 52-Week Low

120.70%%